Dr. Min Shi 石敏
Chief Physician, Associate Professor
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for digestive tumors, including colorectal, gastric, esophageal, and liver cancers. Also treats lung, ovarian, and head and neck tumors. Focuses on individualized comprehensive treatment and full-course management of gastrointestinal malignancies.
Dr. Shi holds a PhD in Oncology and serves as Associate Professor and Deputy Department Director at Nanfang Hospital. With over 20 years of experience, Dr. Shi focuses on translational research in gastrointestinal tumor metabolism, metastasis, and microenvironment. Dr. Shi leads two National Natural Science Foundation projects and has published 24 SCI papers.
Professional roles
- Vice Chair, Anti-Tumor Drug Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, Tumor Prevention and Treatment Professional Committee, Guangdong Preventive Medicine Association
Name order: in Chinese the family name comes first (Shi Min). Papers usually list the name as Min Shi or Shi M.
Selected publications
91 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Immunother Cancer, 2025 (senior author): Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation. PubMed 39947814
- Cell Rep Med, 2024 (first author): Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy. PubMed 39631402
- Med, 2024 (first author): Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial. PubMed 39089261
- Theranostics, 2024 (senior author): Erratum: Adipocytes fuel gastric cancer omental metastasis via PITPNC1-mediated fatty acid metabolic reprogramming: Erratum. PubMed 39310096
- Cell Metab, 2024 (senior author): Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. PubMed 38897198
- J Transl Med, 2024 (senior author): Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer. PubMed 39097734
- Cancer Lett, 2024 (senior author): Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. PubMed 38336288
- Cancer Commun (Lond), 2023 (senior author): Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. PubMed 37434399
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion